research Advanced Breast Cancer in Young Women
The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.
Search
for
Sort by
Research
30 / 1000+ results 
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Outcome and Clinical-Biological Characteristics of Patients with Advanced Breast Cancer Undergoing Removal of Ovarian/Pelvic Metastases
Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
research Understanding Key Symptoms, Side Effects, and Impacts of HR+/HER2- Advanced Breast Cancer: Qualitative Study Findings
Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
research Gemcitabine in Combination with Vinorelbine in Elderly Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Diagnostic Value of VDR in Bone Metastasis and Prognosis of Patients with Breast Cancer and Expression Correlation Between Vitamin D Receptor and Hairless Protein
Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Drug Safety Evaluation of Exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research Is Dehydroepiandrosterone a Hormone?
Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
research High Incidence of Severe Hand-Foot Syndrome During Capecitabine-Docetaxel Combination Chemotherapy
About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research First-Line Therapy with Gemcitabine and Paclitaxel in Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
research Permanent Scalp Alopecia Related to Breast Cancer Chemotherapy by Sequential Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and Docetaxel: A Prospective Study of 20 Patients
Some breast cancer chemotherapy can cause permanent hair loss.
research Aromatase Inhibitor Therapy and Hair Loss Among Breast Cancer Survivors
Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer
Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
research Interaction Between Estrogens and Androgen Receptor Genes Microsatellites, Prostate-Specific Antigen, and Androgen Receptor Expressions in Breast Cancer
Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.
research Scalp Cooling Has No Place in the Prevention of Alopecia in Adjuvant Chemotherapy for Breast Cancer
Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.
research The Evolution of Primary Multimodality Treatment in Resectable Breast Cancer
Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
research Cost-Effectiveness of Palliative Chemotherapy in Advanced Gastrointestinal Cancer
Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.
research Androgen Receptor: A Promising Therapeutic Target in Breast Cancer
The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
research Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX/Doxil) Versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer
Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
research Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel
Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
research Doxil (Caelyx): An Exploratory Study with Pharmacokinetics in Patients with Hormone-Refractory Prostate Cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research The Chinese Herb Xiaoaiping Protects Against Breast Cancer Chemotherapy-Induced Alopecia and Other Side Effects: A Randomized Controlled Trial
Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.